Sync local dataset files and folders

data_en/constraint/{climategov_001.json → climategov_011.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "climategov_001",
+  "task_id": "climategov_011",
   "domain": "NOAA_NCEI_CLIMATE_AT_A_GLANCE",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 3,

data_en/constraint/{climategov_002.json → climategov_012.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "climategov_002",
+  "task_id": "climategov_012",
   "domain": "NOAA_NCEI_CLIMATE_AT_A_GLANCE",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 2,

data_en/constraint/{comptox_001.json → comptox_010.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "comptox_001",
+  "task_id": "comptox_010",
   "domain": "COMPTOX_CHEMEXPO",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 5,

data_en/constraint/{comptox_002.json → comptox_011.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "comptox_002",
+  "task_id": "comptox_011",
   "domain": "COMPTOX_CHEMEXPO",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 6,

data_en/constraint/{comptox_003.json → comptox_012.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "comptox_003",
+  "task_id": "comptox_012",
   "domain": "COMPTOX_CHEMEXPO",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 2,

data_en/constraint/{comptox_004.json → comptox_013.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "comptox_004",
+  "task_id": "comptox_013",
   "domain": "COMPTOX_CHEMEXPO",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 5,

data_en/constraint/{consumerfinance_001.json → consumerfinance_008.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "consumerfinance_001",
+  "task_id": "consumerfinance_008",
   "domain": "CFPB_REPORTS",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 3,

data_en/constraint/{consumerfinance_002.json → consumerfinance_009.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "consumerfinance_002",
+  "task_id": "consumerfinance_009",
   "domain": "CFPB_REPORTS",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 2,

data_en/constraint/{consumerfinance_003.json → consumerfinance_010.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "consumerfinance_003",
+  "task_id": "consumerfinance_010",
   "domain": "CFPB_REPORTS",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 2,

data_en/constraint/{consumerfinance_004.json → consumerfinance_011.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "consumerfinance_004",
+  "task_id": "consumerfinance_011",
   "domain": "CFPB_REPORTS",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 2,

data_en/constraint/{consumerfinance_005.json → consumerfinance_012.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "consumerfinance_005",
+  "task_id": "consumerfinance_012",
   "domain": "CFPB_COMPLAINT_DATABASE",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 2,

data_en/constraint/{consumerfinance_006.json → consumerfinance_013.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "consumerfinance_006",
+  "task_id": "consumerfinance_013",
   "domain": "CFPB_COMPLAINT_DATABASE",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 2,

data_en/constraint/{consumerfinance_007.json → consumerfinance_014.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "consumerfinance_007",
+  "task_id": "consumerfinance_014",
   "domain": "CFPB_COMPLAINT_DATABASE",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 4,

data_en/constraint/{nvd_003.json → nvd_004.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "nvd_003",
+  "task_id": "nvd_004",
   "domain": "NVD",
   "autonomy_type": "ordered table",
   "instruction": "We are cleaning up a batch of old SBOM matching rules that still represent Apache Tomcat 9.0.0 pre-release milestone versions using the legacy CPE form 9.0.0.Mx. We need to identify which milestone versions satisfy both of the following conditions: (1) they appear in the current NVD affected-product version ranges for the four historical vulnerabilities CVE-2016-5018, CVE-2016-6794, CVE-2016-6796, and CVE-2016-6797; and (2) the NVD change history shows that the CPE for these versions was remapped from the old short form (e.g., m1, m2) to the full form (e.g., milestone1, milestone2). Start from the Apache Tomcat 9.0.0 milestone versions, check each against the current NVD affected-product version ranges for these four CVEs, then examine the corresponding change history records. Retain only those milestone versions that satisfy both conditions. Exclude milestones that are included only because of other Tomcat 9.0.0 pre-release vulnerabilities, and do not include Tomcat 6, 7, 8, 8.5, or any non-Tomcat products. Finally, output an ordered multi-row table sorted by milestone number in ascending order, with columns: milestone | legacy_cpe | current_cpe | required_cves | remap_time_nvd.",

data_en/constraint/{wonder_001.json → wonder_003.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "wonder_001",
+  "task_id": "wonder_003",
   "domain": "CDC_WONDER",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 8,

data_en/constraint/{wonder_002.json → wonder_004.json}

@@ -1,12 +1,12 @@
 {
-  "task_id": "wonder_002",
+  "task_id": "wonder_004",
   "domain": "CDC_WONDER",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 3,
   "instruction": "I am preparing a one-page public health brief on 2021 U.S. infant mortality disparities. I want to identify groups that are separately listed in the report by mother's race and Hispanic origin, have an infant mortality rate above the U.S. overall rate, and have a clearly identifiable leading cause of death. First, from the separately listed groups in the report, select those with an infant mortality rate above the U.S. overall rate and a clearly identifiable leading cause of death. Then, for each qualifying group, record the full-year infant mortality rate, the neonatal rate (under 28 days), and the postneonatal rate (28 days and older), along with the group's leading cause of death, its cause-specific rate, and the rank of that cause among all infant causes. Finally, output a multi-row pipe-delimited table sorted by full-year infant mortality rate from high to low: group|infant_rate|neonatal_rate|postneonatal_rate|top_cause|cause_rate|us_rank.",
   "start_url": "https://wonder.cdc.gov/lbd-current-expanded.html",
   "output_format": "Finally, output a multi-row pipe-delimited table sorted by full-year infant mortality rate from high to low: group|infant_rate|neonatal_rate|postneonatal_rate|top_cause|cause_rate|us_rank.",
-  "oracle_answer": "group|infant_rate|neonatal_rate|postneonatal_rate|top_cause|cause_rate|us_rank\nnon-Hispanic Black|10.55|6.35|4.19|Short gestation and low birth weight|196.4|2\nnon-Hispanic American Indian or Alaska Native|7.46|3.83|3.67|Congenital malformations|134.0|1\nPuerto Rican|6.05|3.93|2.13|Short gestation and low birth weight|108.9|2",
+  "oracle_answer": "group|infant_rate|neonatal_rate|postneonatal_rate|top_cause|cause_rate|us_rank\nBlack non-Hispanic|10.55|6.35|4.19|Short gestation and low birth weight|196.4|2\nAmerican Indian or Alaska Native non-Hispanic|7.46|3.83|3.67|Congenital malformations|134.0|1\nPuerto Rican Hispanic|6.05|3.93|2.13|Short gestation and low birth weight|108.9|2",
   "metadata": {
     "State-Gated Retrieval": [
       "Retain only groups that are separately listed in the 2021 U.S. infant mortality statistics, have a full-year infant mortality rate above the U.S. overall rate, and have a clearly identifiable leading cause of death.",

data_en/goal/genome_003-g.json

@@ -1,64 +1,78 @@
 {
-  "task_id": "genome_004-g",
-  "domain": "KEGG_BRITE",
+  "task_id": "genome_003-g",
+  "domain": "KEGG_GENOME",
   "autonomy_type": "ordered table",
-  "oracle_output_cardinality": 8,
-  "instruction": "I am compiling an ordered table of systemic drugs approved for plaque psoriasis in Japan. Include only active ingredients that were approved in Japan by the end of 2024, are used for systemic treatment of plaque psoriasis, and target the IL-17/IL-23 signaling axis. Exclude topical drugs and systemic drugs acting through other axes. Output multiple rows sorted by Japan first approval date from earliest to latest; for drugs approved on the same day, sort by DRUG_ID ascending. Each row format: <DRUG_ID>|<Name>|<ATC>|<Target_branch>|<PMDA_date>.",
-  "start_url": "https://www.kegg.jp/brite/br08301",
-  "output_format": "Output multiple rows sorted by Japan first approval date from earliest to latest; for drugs approved on the same day, sort by DRUG_ID ascending. Each row format: <DRUG_ID>|<Name>|<ATC>|<Target_branch>|<PMDA_date>.",
-  "oracle_answer": "D09967|Secukinumab|L04AC10|IL17A|2014/12/26\nD10061|Brodalumab|L04AC12|IL17RA|2016/7/4\nD10071|Ixekizumab|L04AC13|IL17A|2016/7/4\nD10438|Guselkumab|L04AC16|IL23A|2018/3/23\nD11052|Risankizumab|L04AC18|IL23A|2019/3/26\nD10400|Tildrakizumab|L04AC17|IL23A|2020/6/29\nD11550|Bimekizumab|L04AC21|IL17A/IL17F|2022/1/20\nD11817|Deucravacitinib|L04AF07|TYK2|2022/9/26",
+  "oracle_output_cardinality": 2,
+  "instruction": "I am preparing a handout for a primate evolution course and want a two-row comparison table for this vitamin C metabolism exception pattern. Output two rows with columns rank|clade_role|parent_clade|clade|anomaly_pathway|contrast_pathway|retained_upstream_module|vitamin_c_synthesis_module|vitamin_c_module_status|example_org|cutoff_year. The first row should be EXCEPTION_CLADE and the second row RETAINED_SISTER_CLADE. Use KEGG organism codes for the example species.",
+  "start_url": "https://www.genome.jp/kegg/kegg2.html",
+  "output_format": "Output a two-row comparison table with columns rank|clade_role|parent_clade|clade|anomaly_pathway|contrast_pathway|retained_upstream_module|vitamin_c_synthesis_module|vitamin_c_module_status|example_org|cutoff_year.",
+  "oracle_answer": "1|EXCEPTION_CLADE|Primates|Haplorrhini|map00053|map00040|M00014|M00129|LOST|csyr|2022\n2|RETAINED_SISTER_CLADE|Primates|Strepsirrhini|map00053|map00040|M00014|M00129|RETAINED|oga|2022",
   "metadata": {
     "State-Gated Retrieval": [
-      "Retain only active ingredients that were approved in Japan by 2024-12-31, are used for systemic treatment of plaque psoriasis, and genuinely act on the IL-17/IL-23 signaling axis.",
-      "The candidate set must cover the ligand side, receptor side, and TYK2 kinase side, not only the interleukin ligand side.",
-      "Final entries sorted by Japan first approval date ascending; for the same date, sort by DRUG_ID ascending."
+      "Search only among primate genome entries established by the end of 2022, and isolate the anomalous lower-level clade that retains the upstream glucuronate module M00014 but lacks the animal-type vitamin C biosynthesis module M00129.",
+      "That anomalous clade must be paired with a sister branch under the same higher-level split, and the sister branch must still retain M00129.",
+      "The final output must place the anomalous branch and the retained sister branch into a two-row comparison table, including the required pathway, module, and example-species fields."
     ],
     "dependency_type": "Data + Control",
     "intra_chain": true,
     "inter_chain": true,
     "data_dependency": [
-      "KEGG disease/drug entry points yield the Japan-approved systemic plaque-psoriasis drug cohort through 2024-12-31",
-      "each drug entry yields target branch, ATC, systemic-use validity, and Japan approval date for IL-17/IL-23-axis candidates",
-      "final rows are produced only after ligand-side, receptor-side, and kinase-side candidates are jointly reconciled and re-sorted by Japan approval date"
+      "the KEGG primate clade pages and genome entries yield candidate subclades and example species established through the cutoff year",
+      "the pathway and module views yield M00014 and M00129 presence/absence evidence for the exception clade and its sister branch",
+      "final rows are produced only after the exception clade and retained sister branch are jointly validated under the same parent split and paired with example organisms"
     ],
     "control_dependency": [
-      "entry-point coverage must include receptor-side IL17RA and kinase-side TYK2 mechanisms when downstream drug pages expose them, rather than staying ligand-only",
-      "Ustekinumab must be removed only when target interpretation shows IL12 + IL23A rather than the IL-17/IL-23-axis criterion required here",
-      "systemic-use, Japanese 3999, and PMDA-date filtering must be applied after each expansion of the candidate set rather than attached to the earlier ligand-only state"
+      "the exception clade remains provisional until both the sister-branch contrast and the example-species checks succeed",
+      "the comparison view must make retained M00014 and missing M00129 visible together",
+      "the two output rows are emitted together only after the exception clade and retained sister branch are fixed under the same parent split"
     ],
     "freeze": {
-      "historical_window": "KEGG plaque-psoriasis systemic-drug entries as objectively existing drug entities, using target-branch and related drug-entry metadata as relatively stable annotations"
+      "historical_window": "the objectively existing primate genome entries established on or before 2022, using current KEGG clade, pathway, and module pages as relatively stable reference information for comparing retained M00014 against lost M00129"
     },
     "answer_type": "multi-row ordered table"
   },
   "rubric": {
     "inclusion_conditions": [
-      "Retain only active ingredients that were approved in Japan by 2024-12-31, are used for systemic treatment of plaque psoriasis, and genuinely act on the IL-17/IL-23 signaling axis.",
-      "The candidate set must cover the ligand side, receptor side, and TYK2 kinase side, not only the interleukin ligand side.",
-      "Final entries sorted by Japan first approval date ascending; for the same date, sort by DRUG_ID ascending."
+      "Search only among primate genome entries established by the end of 2022, and isolate the anomalous lower-level clade that retains the upstream glucuronate module M00014 but lacks the animal-type vitamin C biosynthesis module M00129.",
+      "That anomalous clade must have a contrastable sister branch, and that sister branch must still retain M00129.",
+      "The final output must place the anomalous branch and the retained sister branch into a two-row comparison table, including the required pathway, module, and example-species fields."
     ],
     "exclusion_conditions": [
-      "Exclude topical drugs, non-systemic drugs, or entries outside the specified historical freeze window.",
-      "Exclude Ustekinumab, whose actual target is IL12 + IL23A, because it does not meet the IL-17/IL-23 axis criterion required here.",
-      "Exclude results that miss Brodalumab or Deucravacitinib due to considering only the ligand side."
+      "Exclude results that stop at Simiiformes without checking the broader boundary and therefore miss Haplorrhini.",
+      "Exclude pathway views that do not make the M00014 versus M00129 contrast visible together.",
+      "Exclude candidate clades that have not been validated against a retained sister branch."
     ],
     "normalization": {
       "field_separator": "|",
       "record_separator": "\n",
       "header_row": "omit the header row; emit data rows only",
       "schema": [
-        "DRUG_ID",
-        "Name",
-        "ATC",
-        "Target_branch",
-        "PMDA_date"
+        "rank",
+        "clade_role",
+        "parent_clade",
+        "clade",
+        "anomaly_pathway",
+        "contrast_pathway",
+        "retained_upstream_module",
+        "vitamin_c_synthesis_module",
+        "vitamin_c_module_status",
+        "example_org",
+        "cutoff_year"
       ],
-      "PMDA_date": "use the canonical KEGG-style date format YYYY/M/D with no zero-padding requirement beyond the source value",
-      "Target_branch": "emit the most specific target branch visible in the source path; when multiple parallel branches survive, join them with `/`",
-      "sorting_or_selection": {
-        "primary": "PMDA_date ascending",
-        "secondary": "DRUG_ID ascending"
-      }
+      "rank": "emit 1 for EXCEPTION_CLADE and 2 for RETAINED_SISTER_CLADE",
+      "clade_role": [
+        "EXCEPTION_CLADE",
+        "RETAINED_SISTER_CLADE"
+      ],
+      "pathway_normalization": "emit KEGG pathway ids with the map prefix",
+      "module_normalization": "emit KEGG module ids with the leading M",
+      "vitamin_c_module_status": [
+        "LOST",
+        "RETAINED"
+      ],
+      "organism_code": "use bare KEGG organism codes in lowercase, not species names",
+      "cutoff_year": "use a four-digit year; this task is frozen at 2022",
+      "sorting_or_selection": "emit rows in the fixed order EXCEPTION_CLADE then RETAINED_SISTER_CLADE"
     }
   }
 }

data_en/goal/genome_004-g.json

@@ -1,78 +1,64 @@
 {
   "task_id": "genome_004-g",
-  "domain": "KEGG_GENOME",
+  "domain": "KEGG_BRITE",
   "autonomy_type": "ordered table",
-  "oracle_output_cardinality": 2,
-  "instruction": "I am preparing a handout for a primate evolution course and want a two-row comparison table for this vitamin C metabolism exception pattern. Output two rows with columns rank|clade_role|parent_clade|clade|anomaly_pathway|contrast_pathway|retained_upstream_module|vitamin_c_synthesis_module|vitamin_c_module_status|example_org|cutoff_year. The first row should be EXCEPTION_CLADE and the second row RETAINED_SISTER_CLADE. Use KEGG organism codes for the example species.",
-  "start_url": "https://www.genome.jp/kegg/kegg2.html",
-  "output_format": "Output a two-row comparison table with columns rank|clade_role|parent_clade|clade|anomaly_pathway|contrast_pathway|retained_upstream_module|vitamin_c_synthesis_module|vitamin_c_module_status|example_org|cutoff_year.",
-  "oracle_answer": "1|EXCEPTION_CLADE|Primates|Haplorrhini|map00053|map00040|M00014|M00129|LOST|csyr|2022\n2|RETAINED_SISTER_CLADE|Primates|Strepsirrhini|map00053|map00040|M00014|M00129|RETAINED|oga|2022",
+  "oracle_output_cardinality": 8,
+  "instruction": "I am compiling an ordered table of systemic drugs approved for plaque psoriasis in Japan. Include only active ingredients that were approved in Japan by the end of 2024, are used for systemic treatment of plaque psoriasis, and target the IL-17/IL-23 signaling axis. Exclude topical drugs and systemic drugs acting through other axes. Output multiple rows sorted by Japan first approval date from earliest to latest; for drugs approved on the same day, sort by DRUG_ID ascending. Each row format: <DRUG_ID>|<Name>|<ATC>|<Target_branch>|<PMDA_date>.",
+  "start_url": "https://www.kegg.jp/brite/br08301",
+  "output_format": "Output multiple rows sorted by Japan first approval date from earliest to latest; for drugs approved on the same day, sort by DRUG_ID ascending. Each row format: <DRUG_ID>|<Name>|<ATC>|<Target_branch>|<PMDA_date>.",
+  "oracle_answer": "D09967|Secukinumab|L04AC10|IL17A|2014/12/26\nD10061|Brodalumab|L04AC12|IL17RA|2016/7/4\nD10071|Ixekizumab|L04AC13|IL17A|2016/7/4\nD10438|Guselkumab|L04AC16|IL23A|2018/3/23\nD11052|Risankizumab|L04AC18|IL23A|2019/3/26\nD10400|Tildrakizumab|L04AC17|IL23A|2020/6/29\nD11550|Bimekizumab|L04AC21|IL17A/IL17F|2022/1/20\nD11817|Deucravacitinib|L04AF07|TYK2|2022/9/26",
   "metadata": {
     "State-Gated Retrieval": [
-      "Search only among primate genome entries established by the end of 2022, and isolate the anomalous lower-level clade that retains the upstream glucuronate module M00014 but lacks the animal-type vitamin C biosynthesis module M00129.",
-      "That anomalous clade must be paired with a sister branch under the same higher-level split, and the sister branch must still retain M00129.",
-      "The final output must place the anomalous branch and the retained sister branch into a two-row comparison table, including the required pathway, module, and example-species fields."
+      "Retain only active ingredients that were approved in Japan by 2024-12-31, are used for systemic treatment of plaque psoriasis, and genuinely act on the IL-17/IL-23 signaling axis.",
+      "The candidate set must cover the ligand side, receptor side, and TYK2 kinase side, not only the interleukin ligand side.",
+      "Final entries sorted by Japan first approval date ascending; for the same date, sort by DRUG_ID ascending."
     ],
     "dependency_type": "Data + Control",
     "intra_chain": true,
     "inter_chain": true,
     "data_dependency": [
-      "the KEGG primate clade pages and genome entries yield candidate subclades and example species established through the cutoff year",
-      "the pathway and module views yield M00014 and M00129 presence/absence evidence for the exception clade and its sister branch",
-      "final rows are produced only after the exception clade and retained sister branch are jointly validated under the same parent split and paired with example organisms"
+      "KEGG disease/drug entry points yield the Japan-approved systemic plaque-psoriasis drug cohort through 2024-12-31",
+      "each drug entry yields target branch, ATC, systemic-use validity, and Japan approval date for IL-17/IL-23-axis candidates",
+      "final rows are produced only after ligand-side, receptor-side, and kinase-side candidates are jointly reconciled and re-sorted by Japan approval date"
     ],
     "control_dependency": [
-      "the exception clade remains provisional until both the sister-branch contrast and the example-species checks succeed",
-      "the comparison view must make retained M00014 and missing M00129 visible together",
-      "the two output rows are emitted together only after the exception clade and retained sister branch are fixed under the same parent split"
+      "entry-point coverage must include receptor-side IL17RA and kinase-side TYK2 mechanisms when downstream drug pages expose them, rather than staying ligand-only",
+      "Ustekinumab must be removed only when target interpretation shows IL12 + IL23A rather than the IL-17/IL-23-axis criterion required here",
+      "systemic-use, Japanese 3999, and PMDA-date filtering must be applied after each expansion of the candidate set rather than attached to the earlier ligand-only state"
     ],
     "freeze": {
-      "historical_window": "the objectively existing primate genome entries established on or before 2022, using current KEGG clade, pathway, and module pages as relatively stable reference information for comparing retained M00014 against lost M00129"
+      "historical_window": "KEGG plaque-psoriasis systemic-drug entries as objectively existing drug entities, using target-branch and related drug-entry metadata as relatively stable annotations"
     },
     "answer_type": "multi-row ordered table"
   },
   "rubric": {
     "inclusion_conditions": [
-      "Search only among primate genome entries established by the end of 2022, and isolate the anomalous lower-level clade that retains the upstream glucuronate module M00014 but lacks the animal-type vitamin C biosynthesis module M00129.",
-      "That anomalous clade must have a contrastable sister branch, and that sister branch must still retain M00129.",
-      "The final output must place the anomalous branch and the retained sister branch into a two-row comparison table, including the required pathway, module, and example-species fields."
+      "Retain only active ingredients that were approved in Japan by 2024-12-31, are used for systemic treatment of plaque psoriasis, and genuinely act on the IL-17/IL-23 signaling axis.",
+      "The candidate set must cover the ligand side, receptor side, and TYK2 kinase side, not only the interleukin ligand side.",
+      "Final entries sorted by Japan first approval date ascending; for the same date, sort by DRUG_ID ascending."
     ],
     "exclusion_conditions": [
-      "Exclude results that stop at Simiiformes without checking the broader boundary and therefore miss Haplorrhini.",
-      "Exclude pathway views that do not make the M00014 versus M00129 contrast visible together.",
-      "Exclude candidate clades that have not been validated against a retained sister branch."
+      "Exclude topical drugs, non-systemic drugs, or entries outside the specified historical freeze window.",
+      "Exclude Ustekinumab, whose actual target is IL12 + IL23A, because it does not meet the IL-17/IL-23 axis criterion required here.",
+      "Exclude results that miss Brodalumab or Deucravacitinib due to considering only the ligand side."
     ],
     "normalization": {
       "field_separator": "|",
       "record_separator": "\n",
       "header_row": "omit the header row; emit data rows only",
       "schema": [
-        "rank",
-        "clade_role",
-        "parent_clade",
-        "clade",
-        "anomaly_pathway",
-        "contrast_pathway",
-        "retained_upstream_module",
-        "vitamin_c_synthesis_module",
-        "vitamin_c_module_status",
-        "example_org",
-        "cutoff_year"
+        "DRUG_ID",
+        "Name",
+        "ATC",
+        "Target_branch",
+        "PMDA_date"
       ],
-      "rank": "emit 1 for EXCEPTION_CLADE and 2 for RETAINED_SISTER_CLADE",
-      "clade_role": [
-        "EXCEPTION_CLADE",
-        "RETAINED_SISTER_CLADE"
-      ],
-      "pathway_normalization": "emit KEGG pathway ids with the map prefix",
-      "module_normalization": "emit KEGG module ids with the leading M",
-      "vitamin_c_module_status": [
-        "LOST",
-        "RETAINED"
-      ],
-      "organism_code": "use bare KEGG organism codes in lowercase, not species names",
-      "cutoff_year": "use a four-digit year; this task is frozen at 2022",
-      "sorting_or_selection": "emit rows in the fixed order EXCEPTION_CLADE then RETAINED_SISTER_CLADE"
+      "PMDA_date": "use the canonical KEGG-style date format YYYY/M/D with no zero-padding requirement beyond the source value",
+      "Target_branch": "emit the most specific target branch visible in the source path; when multiple parallel branches survive, join them with `/`",
+      "sorting_or_selection": {
+        "primary": "PMDA_date ascending",
+        "secondary": "DRUG_ID ascending"
+      }
     }
   }
 }

data_en/goal/{wonder_002-g.json → wonder_004-g.json}

@@ -6,7 +6,7 @@
   "instruction": "From the 2021 U.S. infant mortality statistics by mother's race and Hispanic origin, identify all groups that are reported separately, have an infant mortality rate above the U.S. overall rate, and have a clearly identifiable leading cause of death. For each qualifying group, provide the infant mortality rate, neonatal mortality rate (under 28 days), postneonatal mortality rate (28 days and older), the group's leading cause of death, the cause-specific rate, and the rank of that cause among all infant causes. Output a multi-row pipe-delimited table sorted by infant mortality rate descending, using the format: group|infant_rate|neonatal_rate|postneonatal_rate|top_cause|cause_rate|us_rank.",
   "start_url": "https://wonder.cdc.gov/lbd-current-expanded.html",
   "output_format": "Output a multi-row pipe-delimited table sorted by infant mortality rate descending, using the format: group|infant_rate|neonatal_rate|postneonatal_rate|top_cause|cause_rate|us_rank.",
-  "oracle_answer": "group|infant_rate|neonatal_rate|postneonatal_rate|top_cause|cause_rate|us_rank\nnon-Hispanic Black|10.55|6.35|4.19|Short gestation and low birth weight|196.4|2\nnon-Hispanic American Indian or Alaska Native|7.46|3.83|3.67|Congenital malformations|134.0|1\nPuerto Rican|6.05|3.93|2.13|Short gestation and low birth weight|108.9|2",
+  "oracle_answer": "group|infant_rate|neonatal_rate|postneonatal_rate|top_cause|cause_rate|us_rank\nBlack non-Hispanic|10.55|6.35|4.19|Short gestation and low birth weight|196.4|2\nAmerican Indian or Alaska Native non-Hispanic|7.46|3.83|3.67|Congenital malformations|134.0|1\nPuerto Rican Hispanic|6.05|3.93|2.13|Short gestation and low birth weight|108.9|2",
   "metadata": {
     "State-Gated Retrieval": [
       "Retain only groups that are reported separately in the 2021 U.S. infant mortality statistics, have an infant mortality rate above the U.S. overall rate, and have a clearly identifiable leading cause of death.",

data_zh/constraint/{climategov_001.json → climategov_011.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "climategov_001",
+  "task_id": "climategov_011",
   "domain": "NOAA_NCEI_CLIMATE_AT_A_GLANCE",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 3,

data_zh/constraint/{climategov_002.json → climategov_012.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "climategov_002",
+  "task_id": "climategov_012",
   "domain": "NOAA_NCEI_CLIMATE_AT_A_GLANCE",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 2,

data_zh/constraint/{comptox_001.json → comptox_010.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "comptox_001",
+  "task_id": "comptox_010",
   "domain": "COMPTOX_CHEMEXPO",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 5,

data_zh/constraint/{comptox_002.json → comptox_011.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "comptox_002",
+  "task_id": "comptox_011",
   "domain": "COMPTOX_CHEMEXPO",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 6,

data_zh/constraint/{comptox_003.json → comptox_012.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "comptox_003",
+  "task_id": "comptox_012",
   "domain": "COMPTOX_CHEMEXPO",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 2,

data_zh/constraint/{comptox_004.json → comptox_013.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "comptox_004",
+  "task_id": "comptox_013",
   "domain": "COMPTOX_CHEMEXPO",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 5,

data_zh/constraint/{consumerfinance_001.json → consumerfinance_008.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "consumerfinance_001",
+  "task_id": "consumerfinance_008",
   "domain": "CFPB_REPORTS",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 3,

data_zh/constraint/{consumerfinance_002.json → consumerfinance_009.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "consumerfinance_002",
+  "task_id": "consumerfinance_009",
   "domain": "CFPB_REPORTS",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 2,

data_zh/constraint/{consumerfinance_003.json → consumerfinance_010.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "consumerfinance_003",
+  "task_id": "consumerfinance_010",
   "domain": "CFPB_REPORTS",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 2,

data_zh/constraint/{consumerfinance_004.json → consumerfinance_011.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "consumerfinance_004",
+  "task_id": "consumerfinance_011",
   "domain": "CFPB_REPORTS",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 2,

data_zh/constraint/{consumerfinance_005.json → consumerfinance_012.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "consumerfinance_005",
+  "task_id": "consumerfinance_012",
   "domain": "CFPB_COMPLAINT_DATABASE",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 2,

data_zh/constraint/{consumerfinance_006.json → consumerfinance_013.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "consumerfinance_006",
+  "task_id": "consumerfinance_013",
   "domain": "CFPB_COMPLAINT_DATABASE",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 2,

data_zh/constraint/{consumerfinance_007.json → consumerfinance_014.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "consumerfinance_007",
+  "task_id": "consumerfinance_014",
   "domain": "CFPB_COMPLAINT_DATABASE",
   "autonomy_type": "ordered table",
   "oracle_output_cardinality": 4,

data_zh/constraint/{nvd_003.json → nvd_004.json}

@@ -1,5 +1,5 @@
 {
-  "task_id": "nvd_003",
+  "task_id": "nvd_004",
   "domain": "NVD",
   "autonomy_type": "ordered table",
   "instruction": "我们在清理一批旧 SBOM 匹配规则，这些规则仍把 Apache Tomcat 9.0.0 发布前的 milestone 版本写成 9.0.0.Mx 这种旧 CPE 写法。现在需要确认，哪些 milestone 版本同时满足两项条件：一是它们都出现在 CVE-2016-5018、CVE-2016-6794、CVE-2016-6796 和 CVE-2016-6797 这四个历史漏洞当前在 NVD 中列出的受影响产品版本范围里；二是能够在 NVD 的历史变更记录中看到，这些版本对应的 CPE 曾从 m1、m2 这类旧写法改成 milestone1、milestone2 这类完整写法。请从 Apache Tomcat 9.0.0 的 milestone 版本入手，逐一核对这四个漏洞当前在 NVD 中列出的受影响产品版本范围，再查看相应的历史变更记录，只保留同时满足这两项条件的 milestone 版本。筛选时，请排除那些只是因为其他 Tomcat 9.0.0 发布前漏洞才被带入的 milestone，也不要纳入 Tomcat 6、7、8、8.5 或任何非 Tomcat 产品。最后，请按 milestone 编号的数值升序输出多行有序表，列为 milestone | legacy_cpe | current_cpe | required_cves | remap_time_nvd。",